Seed Funding

A whiteboard saying transition

From Series A to B: Navigating the transition from promise to proof From Series A to B: Navigating the transition from promise to proof

Investors at LSX Investival discuss how, after securing Series A funding, biotech companies should begin to lay the groundwork for Series B financing.

byMillie Nelson

Nov 20, 2024

|

1 Min Read

Europe’s adversity to risk is why the US is ahead, say experts Europe’s adversity to risk is why the US is ahead

byMillie Nelson

Nov 5, 2024

1 Min Read

'Is the worst behind us?' Financial expert talks biotech funding 'Is the worst behind us?' Financial expert talks biotech funding

byBrian Scanlan, Dan Stanton

Oct 21, 2024

1 Min Read

The rise of radiopharmaceuticals sees big pharma back Aktis’ $175m Series B The rise of radiopharmaceuticals sees big pharma back Aktis’ $175m Series B

byMillie Nelson

Oct 17, 2024

1 Min Read

Overhead view of business people working and funding

$325 million Series C funding in its Arsenal (Biosciences)$325 million Series C funding in its Arsenal (Biosciences)

byMillie Nelson

Sep 25, 2024

1 Min Read

People making business deals

Prometheus and Merck: Under the bonnet of the largest pre-Phase III M&A deal Under the bonnet of the largest pre-Phase III M&A deal

byMillie Nelson

Sep 25, 2024

1 Min Read

GSK, Novartis, Calliditas among winners at LSX Awards

GSK, Novartis, Calliditas among winners at LSX Awards

byMillie Nelson

Subscribe to Our Newsletters

Stay updated and receive your insights for life sciences investment, innovation and partnering directly in your inbox.